RxDoctor Payments Data

Jacquelyn Plick

Adult Health · New Brunswick, NJNPI 1609026665

Payments from drug & device makers

$1,076in general payments, 2019–2025

Across 33 payments — averaging $32.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$285
  • Tandem Diabetes Care, Inc.$206
  • Insulet Corporation$168
  • Sanofi-aventis U.S. LLC$104
  • Novo Nordisk$64
  • Corcept Therapeutics$47
  • plus $202 from 8 others

What the payments were for

  • Food & beverage$1,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,076 in reported general payments places this provider in the 70th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$37,868
Medicare patients
116
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$122,900
MounjaroTirzepatide76$80,467
TrulicityDulaglutide35$45,363
Tresiba Flextouch U-100Insulin Degludec33$27,611
JardianceEmpagliflozin33$27,553
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$21,207
Lantus SolostarInsulin Glargine,hum.Rec.Anlog175$20,611
JanuviaSitagliptin Phosphate15$16,756
Fiasp FlextouchInsulin Aspart (Niacinamide)25$16,378
FarxigaDapagliflozin Propanediol22$15,894
Humalog Kwikpen U-100Insulin Lispro77$15,012
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$11,534
Humulin R U-500 KwikpenInsulin Regular, Human15$8,623
HumalogInsulin Lispro42$8,474
Insulin Lispro Kwikpen U-100Insulin Lispro48$8,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$64$129,354104 claims
Boehringer IngelheimJardiance$23$27,55333 claims
Cequr CorporationCequr Simplicity$18$7,74615 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$34837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,135 adult health providers in New Jersey.

Other adult health in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →